Baclofen 10mg / 25mg (Lioresal Generic)
Clinical guidance, bioequivalence criteria, and verified partner dispensing standards for Baclofen 10mg / 25mg (Lioresal Generic). Reviewed by board-certified internal medicine and clinical pharmacotherapy specialists.
Baclofen (Lioresal) — Dosage Strengths & Online Availability
| Dosage Strength | Pack Supply | Dispensary Price | Stock Status | Verified Order |
|---|---|---|---|---|
| Baclofen 10mg | Oral Tablets • 30 / 60 Units | $2.38 / unit | ✓ In Stock (US Dispatch) | Select & Check Price ↗ |
| Baclofen 25mg POPULAR | Oral Tablets • 60 / 90 Units (Most Popular) | $1.27 / unitPOPULAR | ✓ In Stock (US Dispatch) | Select & Check Price ↗ |
1. Clinical Dosing & Titration Protocols
Daily / Baseline Regimen
Initiate at 5mg three times daily (TID) for 3 days; escalate by 5mg per dose every 3 days up to 10mg–20mg TID (max 80mg/day).
On-Demand / Titration Regimen
Must be titrated gradually and NEVER abruptly discontinued (risk of acute withdrawal seizures).
Renal Impairment: Reduce dose by 50% due to exclusive renal elimination.
2. Patient Administration & Safe Usage Guidelines
Do not drive or operate machinery until tolerance is established. Never stop taking abruptly; always taper down over 1–2 weeks.
Verified Telehealth Access Standards for Baclofen 10mg / 25mg (Lioresal Generic)
Our clinical editorial board audits certified partner telehealth dispensaries to guarantee authentic WHO-GMP manufacturing, analytical batch testing, and physician-supervised asynchronous consultation.
Check Telehealth Protocol & Availability ↗3. Frequently Asked Patient Questions
How does Baclofen work on GABA-B receptors?
Baclofen binds pre-synaptic GABA-B receptors in the spinal cord, hyperpolarizing neurons and inhibiting the release of excitatory neurotransmitters (glutamate and aspartate).
Why must Baclofen be tapered when stopping?
Abrupt cessation can cause severe rebound spasticity, hallucinations, autonomic tachycardia, and withdrawal seizures. Always taper slowly under clinical guidance.
4. Pharmacological Mechanism & Receptor Profile
Centrally-acting GABA-B agonist that suppresses mono- and polysynaptic spinal reflexes, relieving skeletal muscle spasticity and reducing central craving neurochemistry.
Cognitive Sciences & Eugeroics • Baclofen 10mg / 25mg (Lioresal Generic)
5. Chemical & Human Pharmacokinetic Matrix (Tmax, Half-Life, CYP450)
| Pharmacokinetic Parameter | Clinical Metric | Therapeutic Significance |
|---|---|---|
| Peak Plasma Time (Tmax) | 1.0 to 2.0 hours | Determines latency from ingestion to peak pharmacological onset. |
| Elimination Half-Life (T½) | 3.0 to 4.0 hours (plasma elimination half-life) | Governs duration of action and steady-state dosing intervals. |
| Peak Concentration (Cmax) | Dose-dependent | Maximum observed systemic concentration in human plasma. |
| Bioavailability & Food Interaction | 70% to 80% | Defines oral bioavailability and dietary lipid dependency. |
| Plasma Protein Binding | 30% | Governs free circulating drug fraction available for receptor binding. |
| Volume of Distribution (Vd) | 0.7 L/kg | Reflects tissue and lipid compartment penetration. |
| Hepatic Metabolism | 15% hepatic deamination; 85% excreted unchanged | Primary enzymatic clearance and CYP pathways. |
| Elimination / Excretion | 70% to 80% excreted unchanged in urine | Renal vs biliary/fecal excretion balance. |
6. Drug-Drug Interaction Matrix
| Interacting Agent / Class | Severity Tier | Clinical Mechanism & Management Strategy |
|---|---|---|
| CNS Depressants / Alcohol / Benzodiazepines | Major Precaution | Profound additive sedation and respiratory depression. |
7. Adverse Reaction Profile & Clinical Incidence Rates
| Adverse Reaction | Incidence Rate | Physiological Mechanism & Mitigation Strategy |
|---|---|---|
| Sedation / Drowsiness | 25% | Dose-dependent; subsides with steady titration. |
| Muscle Weakness / Hypotonia | 10% | Excessive muscle tone reduction. |
| Dizziness | 8% | Central GABAergic response. |
Peer-Reviewed Scientific Citations & FDA References
- Dario A, Tomei G. A benefit-risk assessment of baclofen in spasticity. Drug Saf. 2004;27(11):799-818.